Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

Completed

• Conditions: Arthritis, Psoriatic; Arthritis, Rheumatoid

• Registration Number: NCT00195377
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

Detailed Description

Not available

Study Timeline

• Study Start: 2003-04
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-19
• Primary Completion: 2006-04
• Study Completion: 2006-04
• Status Verified: 2009-06
• Last Update Submitted: 2009-06-17
• Last Update Posted: 2009-06-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

• RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate
• Children from 4 to 17 years old with JIA polyarticular

Exclusion Criteria

• Clinically significant abnormal screening lab values
• Patients who are planning to undergo elective surgery during the study period.
• Other current autoimmune connective tissue diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified